#South Korea #Seoul #Botulinum Toxin #SOLTOX #CELSET

CELSET Launches SOLTOX: A New Player in Medical Aesthetics

On October 28, 2026, CELSET INC., a prominent South Korean biotechnology firm specializing in medical aesthetics, announced the launch of its botulinum toxin type A product, SOLTOX. This initiative marks a significant step in expanding Korean innovations within the international medical aesthetics market.

Understanding SOLTOX

SOLTOX is made available in two versions: 100 units and 200 units. The product boasts three key technical features, including a 900 kDa molecular weight toxin complex, a lyophilized drug form, and an advanced purification process. These attributes highlight CELSET's commitment to quality, focusing on controlled processing, product characterization, and pharmaceutical standards.

The 900 kDa molecular weight indicates the size of the botulinum toxin protein complex, along with accompanying proteins. It’s essential to note that this specification reflects the composition rather than making unverified claims about clinical efficacy or duration of effect. SOLTOX is provided as a lyophilized powder that requires reconstitution prior to administration by qualified healthcare professionals, aligning with local regulatory requirements and product labeling instructions.

Manufacturing Excellence

CELSET places a strong emphasis on the purification process, utilizing advanced technologies during the processing of botulinum toxin type A. The production procedure focuses on separating the desired substances from unwanted materials, ensuring that controlled conditions and quality control procedures are met throughout the process, including preparing, filling, lyophilizing, and evaluating production batches. These manufacturing characteristics serve as the technical foundation of the SOLTOX brand.

Market Positioning and Strategy

The introduction of SOLTOX is strategically positioned to highlight the product’s unique composition and rigorous process controls. CELSET aims to create a brand identity that stands out in the competitive landscape of medical aesthetics while avoiding unverified claims about treatment outcomes. By merging technical specifications with a clear brand message, SOLTOX is designed to be easily recognizable across the aesthetic medicine sector.

This product launch positions CELSET to fortify its presence in the global medical aesthetics arena, reflecting the evolving dynamics of Korean biotechnology. It highlights the importance of established medical channels and regulatory frameworks specific to various markets. Moreover, CELSET views market development at the country level and professional relationships as essential components of SOLTOX's international presence.

Commitment to Quality and Professional Communication

The launch of SOLTOX enriches CELSET's portfolio of medical aesthetic products, pivoting on scientifically-backed product communication. The company prioritizes consistent brand presentation and clear information dissemination for healthcare professionals across different markets. Accessibility and usage conform to national regulatory requirements, ensuring compliance and safety.

About CELSET INC.

Headquartered in Seoul, South Korea, CELSET INC. is committed to advancing the medical aesthetics sector. The SOLTOX brand embodies the company’s dedication to introducing unique products that uphold manufacturing principles within aesthetic medicine. As the global aesthetic medicine industry evolves, CELSET emphasizes its role in fostering innovation and professional communication.

For inquiries, visit CELSET Aesthetics.